Neurobiological Technologies Stock Probability Of Bankruptcy
| NTIIDelisted Stock | USD 0.0001 0.00 0.00% |
Neurobiological |
Neurobiological Technologies Company probability of distress Analysis
Neurobiological Technologies' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Neurobiological Technologies Probability Of Bankruptcy | Over 100% |
Most of Neurobiological Technologies' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobiological Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Neurobiological Technologies probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Neurobiological Technologies odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Neurobiological Technologies financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Neurobiological Technologies has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Biotechnology sector and 82.35% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Neurobiological Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobiological Technologies' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobiological Technologies could also be used in its relative valuation, which is a method of valuing Neurobiological Technologies by comparing valuation metrics of similar companies.Neurobiological Technologies is currently under evaluation in probability of bankruptcy category among its peers.
Neurobiological Fundamentals
| Return On Equity | 1.0 | ||||
| Profit Margin | 0.74 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | (26.24 M) | ||||
| Shares Outstanding | 27.02 M | ||||
| Shares Owned By Institutions | 9.41 % | ||||
| Number Of Shares Shorted | 37.6 K | ||||
| Price To Book | 0.07 X | ||||
| Price To Sales | 0.0004 X | ||||
| Revenue | 6.03 M | ||||
| Gross Profit | 26.35 M | ||||
| EBITDA | 19.54 M | ||||
| Net Income | 4.94 M | ||||
| Cash And Equivalents | 26.49 M | ||||
| Cash Per Share | 0.98 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | 4.78 M | ||||
| Short Ratio | 0.09 X | ||||
| Target Price | 6.0 | ||||
| Beta | -408.27 | ||||
| Market Capitalization | 10.86 K | ||||
| Total Asset | 2.58 M | ||||
| Working Capital | (73 K) | ||||
| Current Liabilities | 73 K | ||||
| Z Score | 27.29 | ||||
| Net Asset | 2.58 M |
About Neurobiological Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobiological Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobiological Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobiological Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Neurobiological Stock
If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |